Scopia Capital Management LP Prothena Corp Public LTD CO Transaction History

Scopia Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $5.31 Million - $7.49 Million	-600,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$10.32 - $14.49 $41.5 Million - $58.2 Million	-4,018,164 Reduced 87.01%	600,000 $7.28 Million
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $6.13 Million - $9.64 Million	701,757 Added 17.92%	4,618,164 $47.6 Million
Q3 2018 Nov 14, 2018	BUY	$12.7 - $15.79 $5.15 Million - $6.4 Million	405,523 Added 11.55%	3,916,407 $51.2 Million
Q2 2018 Aug 14, 2018	BUY	$10.99 - $44.21 $38.6 Million - $155 Million	3,510,884 New	3,510,884 $51.2 Million

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Scopia Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Scopia Capital Management LP with notifications on news.